-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Enlivex Therapeutics Ltd. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2015 to Q2 2024.
- Enlivex Therapeutics Ltd. Operating Income (Loss) for the quarter ending June 30, 2024 was -$2.99M, a 55.1% increase year-over-year.
- Enlivex Therapeutics Ltd. annual Operating Income (Loss) for 2023 was -$29.4M, a 13.9% decline from 2022.
- Enlivex Therapeutics Ltd. annual Operating Income (Loss) for 2022 was -$25.8M, a 33.7% decline from 2021.
- Enlivex Therapeutics Ltd. annual Operating Income (Loss) for 2021 was -$19.3M, a 97.1% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)